Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PC-mAb 3G10 in arterial inflammation with elevated lipoprotein(a)
2017-002106-13Phase 2Terminated
- Sponsor
- Athera Biotechnologies AB
- Start
- Jun 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in arteritis, atherosclerotic disease and lipoprotein(a) hyperlipoproteinemia (Lp(a)) comparing PC-mAb 3G10 with Placebo (2 arms). Started Jun 2017; status: terminated.
02
Drugs
ABR-001
03
Conditions
arteritisatherosclerotic diseaselipoprotein(a) hyperlipoproteinemia (Lp(a))
Beyond the preview
Go deeper on 2017-002106-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002106-13.